LARGE TRIM:8.5”
BLEED:8.75” TRIM:7.75” SAFETY:6.75”
INVOKANA® (canagliflozin) starting dose: 100 mg once daily. In patients tolerating the starting dose who have an eGFR ≥60 mL/min/1.73 m2 and require additional glycemic control, the dose can be increased to 300 mg once daily.2
IMPORTANT SAFETY INFORMATION (cont’d) WARNINGS and PRECAUTIONS >> Hypotension: INVOKANA® causes intravascular volume contraction. Symptomatic hypotension can occur after initiating INVOKANA®, particularly in patients with impaired renal function (eGFR <60 mL/min/1.73 m2), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system, or patients with low systolic blood pressure. Before initiating in patients with ≥1 of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms after initiating >> Impairment in Renal Function: INVOKANA® increases serum creatinine and decreases eGFR. Patients with hypovolemia may be more susceptible to these changes. Renal function abnormalities can occur after initiation. More frequent renal function monitoring is recommended in patients with an eGFR <60 mL/min/1.73 m2
033360-150417_INVOKANA_Journal_ad_A_FR2.indd 2
6/10/15 1:12 PM
THIS ADVERTISEMENT PREPARED BY NeON Client: J&J Product: INVOKANA Job#: 10304019 Job Name: A-Size Ad Code: 033360-150417
10304019
Colors: 4C Sizes: B leed: 8.75" W x 11.5" H Trim: 7.75" W x 10.5" H Live: 6.75" W x 9.5" H
Publications:
1/2 Page: Trim: 3.25” W x 9.5” H
Creative Evolution Ads A-SIZE
LARGE TRIM:11”
GO FURTHER
TRIM:10.5”
INSPIRE PATIENTS TO
BLEED:11.5”
SAFETY:9.5”
In the treatment of type 2 diabetes, help
LARGE TRIM:8.5”
BLEED:8.75” TRIM:7.75” SAFETY:6.75”
GREATER REDUCTIONS in A1C2
INVOKANA® 300 mg demonstrated greater reductions in A1C vs Januvia® 100 mg at 52 weeks in patients inadequately controlled on metformin + a sulfonylurea2 Adjusted Mean Change in A1C From Baseline (%) Mean baseline:
8.13%
8.12%
–0.66
–0.37% difference*
–1.03 Januvia® (sitagliptin) 100 mg + metformin and a sulfonylurea (n=378)
INVOKANA® 300 mg + metformin and a sulfonylurea (n=377)
*95% CI: –0.50, –0.25; P0.05.
Secondary endpoint:
Secondary endpoint:
GREATER REDUCTIONS 2
GREATER REDUCTIONS 3
Difference from Januvia® 100 mg: –2.8%; P<0.001
Difference from Januvia® 100 mg: –5.9 mm Hg; P<0.001
Incidence of hypoglycemia2
Adverse events (AEs)3
INVOKANA® 300 mg: 43.2%; Januvia® 100 mg: 40.7% The incidence of hypoglycemia increases when used in combination with insulin or an insulin secretagogue.
Incidences of AEs were similar between groups except for: Male/female genital mycotic infection, INVOKANA® 300 mg: 9.2%/15.3%; Januvia® 100 mg: 0.5%/4.3% Increased urine frequency/volume, INVOKANA® 300 mg: 1.6%/0.8%; Januvia® 100 mg: 1.3%/0%
in systolic blood pressure †
in body weight †
>> Hyperkalemia: INVOKANA® can lead to hyperkalemia. Patients with moderate renal impairment who are taking medications that interfere with potassium excretion or medications that interfere with the renin-angiotensin-aldosterone system are more likely to develop hyperkalemia. Monitor serum potassium levels periodically in patients with impaired renal function and in patients predisposed to hyperkalemia due to medications or other medical conditions >> Hypoglycemia With Concomitant Use With Insulin and Insulin Secretagogues: INVOKANA® can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with INVOKANA® >> Genital Mycotic Infections: INVOKANA® increases risk of genital mycotic infections. Patients with history of these infections and uncircumcised males were more likely to develop these infections. Monitor and treat appropriately >> Hypersensitivity Reactions: Hypersensitivity reactions (eg, generalized urticaria), some serious, were reported with INVOKANA®; these reactions generally occurred within hours to days after initiation. If reactions occur, discontinue INVOKANA®, treat per standard of care, and monitor until signs and symptoms resolve Please see additional Important Safety Information and brief summary of full Prescribing Information on the following pages.
033360-150417_INVOKANA_Journal_ad_A_FR2.indd 3
6/10/15 1:12 PM
THIS ADVERTISEMENT PREPARED BY NeON Client: J&J Product: INVOKANA Job#: 10304019 Job Name: A-Size Ad Code: 033360-150417
10304019
Colors: 4C Sizes: Bleed: 8.75" W x 11.5" H Trim: 7.75" W x 10.5" H Live: 6.75" W x 9.5" H
Publications:
1/2 Page: Trim: 3.25” W x 9.5” H
Creative evolution ads
a-siZe
LARGE TRIM:11”
A randomized, double-blind, active-controlled, 52-week study of patients with type 2 diabetes inadequately controlled on maximally or near-maximally effective doses of metformin (≥2000 mg/day, or ≥1500 mg/day if higher dose not tolerated) and a sulfonylurea.3
TRIM:10.5”
INVOKANAhcp.com
BLEED:11.5”
Learn more and register for updates at
SAFETY:9.5”
INVOKANA® is not indicated for weight loss or as an antihypertensive treatment. †Adjusted mean change from baseline. Indicated trademarks are registered trademarks of their respective owners.